205 related articles for article (PubMed ID: 31134486)
1. eIF2B Mutations Cause Mitochondrial Malfunction in Oligodendrocytes.
Herrero M; Mandelboum S; Elroy-Stein O
Neuromolecular Med; 2019 Sep; 21(3):303-313. PubMed ID: 31134486
[TBL] [Abstract][Full Text] [Related]
2. The Energy Status of Astrocytes Is the Achilles' Heel of eIF2B-Leukodystrophy.
Herrero M; Daw M; Atzmon A; Elroy-Stein O
Cells; 2021 Jul; 10(8):. PubMed ID: 34440627
[TBL] [Abstract][Full Text] [Related]
3. Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease.
Raini G; Sharet R; Herrero M; Atzmon A; Shenoy A; Geiger T; Elroy-Stein O
J Neurochem; 2017 Jun; 141(5):694-707. PubMed ID: 28306143
[TBL] [Abstract][Full Text] [Related]
4. Impaired eukaryotic translation initiation factor 2B activity specifically in oligodendrocytes reproduces the pathology of vanishing white matter disease in mice.
Lin Y; Pang X; Huang G; Jamison S; Fang J; Harding HP; Ron D; Lin W
J Neurosci; 2014 Sep; 34(36):12182-91. PubMed ID: 25186761
[TBL] [Abstract][Full Text] [Related]
5. Poor cerebral inflammatory response in eIF2B knock-in mice: implications for the aetiology of vanishing white matter disease.
Cabilly Y; Barbi M; Geva M; Marom L; Chetrit D; Ehrlich M; Elroy-Stein O
PLoS One; 2012; 7(10):e46715. PubMed ID: 23056417
[TBL] [Abstract][Full Text] [Related]
6. Proteomics-level analysis of myelin formation and regeneration in a mouse model for Vanishing White Matter disease.
Gat-Viks I; Geiger T; Barbi M; Raini G; Elroy-Stein O
J Neurochem; 2015 Aug; 134(3):513-26. PubMed ID: 25920008
[TBL] [Abstract][Full Text] [Related]
7. Astrocytes are central in the pathomechanisms of vanishing white matter.
Dooves S; Bugiani M; Postma NL; Polder E; Land N; Horan ST; van Deijk AL; van de Kreeke A; Jacobs G; Vuong C; Klooster J; Kamermans M; Wortel J; Loos M; Wisse LE; Scheper GC; Abbink TE; Heine VM; van der Knaap MS
J Clin Invest; 2016 Apr; 126(4):1512-24. PubMed ID: 26974157
[TBL] [Abstract][Full Text] [Related]
8. Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.
Terumitsu-Tsujita M; Kitaura H; Miura I; Kiyama Y; Goto F; Muraki Y; Ominato S; Hara N; Simankova A; Bizen N; Kashiwagi K; Ito T; Toyoshima Y; Kakita A; Manabe T; Wakana S; Takebayashi H; Igarashi H
J Neurochem; 2020 Jul; 154(1):25-40. PubMed ID: 31587290
[TBL] [Abstract][Full Text] [Related]
9. Vanishing white matter: deregulated integrated stress response as therapy target.
Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
[TBL] [Abstract][Full Text] [Related]
10. Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy.
Atzmon A; Herrero M; Sharet-Eshed R; Gilad Y; Senderowitz H; Elroy-Stein O
Front Mol Neurosci; 2018; 11():336. PubMed ID: 30279648
[TBL] [Abstract][Full Text] [Related]
11. Vanishing white matter: a leukodystrophy due to astrocytic dysfunction.
Bugiani M; Vuong C; Breur M; van der Knaap MS
Brain Pathol; 2018 May; 28(3):408-421. PubMed ID: 29740943
[TBL] [Abstract][Full Text] [Related]
12. Human-induced pluripotent stem cell-derived cerebral organoid of leukoencephalopathy with vanishing white matter.
Deng J; Zhang J; Gao K; Zhou L; Jiang Y; Wang J; Wu Y
CNS Neurosci Ther; 2023 Apr; 29(4):1049-1066. PubMed ID: 36650674
[TBL] [Abstract][Full Text] [Related]
13. A point mutation in translation initiation factor eIF2B leads to function--and time-specific changes in brain gene expression.
Marom L; Ulitsky I; Cabilly Y; Shamir R; Elroy-Stein O
PLoS One; 2011; 6(10):e26992. PubMed ID: 22073122
[TBL] [Abstract][Full Text] [Related]
14. Leukoencephalopathy with vanishing white matter: a review.
Bugiani M; Boor I; Powers JM; Scheper GC; van der Knaap MS
J Neuropathol Exp Neurol; 2010 Oct; 69(10):987-96. PubMed ID: 20838246
[TBL] [Abstract][Full Text] [Related]
15. Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations.
Slynko I; Nguyen S; Hamilton EMC; Wisse LE; de Esch IJP; de Graaf C; Bruning JB; Proud CG; Abbink TEM; van der Knaap MS
Mol Genet Genomic Med; 2021 Mar; 9(3):e1593. PubMed ID: 33432707
[TBL] [Abstract][Full Text] [Related]
16. Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response.
Keefe MD; Soderholm HE; Shih HY; Stevenson TJ; Glaittli KA; Bowles DM; Scholl E; Colby S; Merchant S; Hsu EW; Bonkowsky JL
Elife; 2020 Dec; 9():. PubMed ID: 33300869
[TBL] [Abstract][Full Text] [Related]
17. A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter.
Geva M; Cabilly Y; Assaf Y; Mindroul N; Marom L; Raini G; Pinchasi D; Elroy-Stein O
Brain; 2010 Aug; 133(Pt 8):2448-61. PubMed ID: 20826436
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease.
Norris K; Hodgson RE; Dornelles T; Allen KE; Abell BM; Ashe MP; Campbell SG
J Biol Chem; 2021; 296():100207. PubMed ID: 33334879
[TBL] [Abstract][Full Text] [Related]
19. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
Pan YX; Wu Y; Niu ZP; Jiang YW
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
[TBL] [Abstract][Full Text] [Related]
20. EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy.
Dietrich J; Lacagnina M; Gass D; Richfield E; Mayer-Pröschel M; Noble M; Torres C; Pröschel C
Nat Med; 2005 Mar; 11(3):277-83. PubMed ID: 15723074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]